Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012. ,
ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol, vol.28, p.3111, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01675165
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, vol.366, pp.109-128, 2012. ,
Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med, vol.355, pp.2733-2776, 2006. ,
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, pp.783-92, 2001. ,
Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, vol.367, pp.1783-91, 2012. ,
Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer, N Engl J Med, vol.366, pp.520-529, 2012. ,
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, vol.17, pp.425-464, 2016. ,
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, vol.16, pp.25-35, 2015. ,
Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, vol.375, pp.1738-1786, 2016. ,
Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer, Crit Rev Oncol Hematol, vol.100, pp.74-87, 2016. ,
Eribulin in the management of advanced breast cancer: implications of current research findings, Breast Cancer (Auckl), vol.9, pp.109-124, 2015. ,
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, vol.377, pp.914-937, 2011. ,
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, vol.33, pp.594-601, 2015. ,
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Ann Oncol, vol.27, pp.1525-1556, 2016. ,
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer, Ann Oncol, vol.23, pp.1441-1449, 2012. ,
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had welldefined taxane resistance, Breast Cancer Res Treat, vol.157, pp.295-305, 2016. ,
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, vol.27, pp.2954-61, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01440451
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study, BMC Cancer, vol.15, p.659, 2015. ,
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial, Eur J Cancer, vol.60, pp.117-141, 2016. ,
Eribulin: rediscovering tubulin as an anticancer target, Clin Cancer Res, vol.15, pp.3903-3908, 2009. ,
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer, Am J Health Syst Pharm, vol.69, pp.745-55, 2012. ,
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies, Breast Cancer Res Treat, vol.148, pp.553-61, 2014. ,
RECIST 1.1-Update and clarification: from the RECIST committee, Eur J Cancer, vol.62, pp.132-139, 2016. ,
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, issue.1, pp.122-50, 2009. ,
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Prev Med, vol.45, pp.247-51, 2007. ,
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer, Breast Cancer Res Treat, vol.107, pp.275-284, 2008. ,
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, Cancer, vol.92, pp.2267-72, 2001. ,
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer, Breast Cancer Res Treat, vol.137, pp.187-93, 2013. ,